EMA appoints Guido Rasi as executive director
pharmafile | October 9, 2015 | Appointment | Medical Communications, Sales and Marketing | EMA, Guido Rasi
The European Medicines Agency’s (EMA’s) Management Board has nominated Professor Guido Rasi as the Executive Director of the Agency.
The Board selected Professor Rasi from a shortlist of candidates provided by the European Commission.
Professor Rasi has been invited to give a statement to the European Parliament’s Committee on the Environment, Public Health and Food Safety (ENVI) on 13 October 2015. The appointment of the new executive director will only be made after this session.
Following his nomination, Professor Rasi says: “I am honoured to have been nominated as EMA’s executive director and am grateful for the opportunity to continue our efforts to make the Agency fit for the challenges ahead. I am enormously proud of the Agency and its network.
“Looking to the future, we must continue to meet patients’ legitimate expectations for access to new and safe therapeutic options. This requires that the medicines authorisation process not only supports the early stages of research and development, but also strives to make the best possible use of real world data throughout a medicine’s lifecycle.”
Chair of the management board, Professor Sir Kent Woods, comments: “The Management Board is pleased to announce the nomination of Guido Rasi as Executive Director of EMA. The decision of the Management Board is the result of a robust recruitment process over the last months. We look forward to Professor Rasi resuming his leadership of the Agency.”
Deputy executive director Andreas Pott will continue to lead EMA operations and to legally represent the Agency until the new executive director has officially taken up his duties.
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence …
Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …
